In Segment A, participants will get different doses and schedules of oral ABBV-744 tablet to recognize Secure dosing routine. Further individuals will probably be enrolled within the identified monotherapy dosign routine. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section C, https://walesm766zkv9.bloginder.com/profile